Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
- Conditions
- Interventions
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 20
- Registration Number
- NCT06710223
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Anwaar Saeed
- Target Recruit Count
- 40
- Registration Number
- NCT06698250
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Single cEll pRofiling PErsistaNce To ImmuNothErapy
- Conditions
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT06680739
- Locations
- 🇪🇸
Vall d'Hebron Institute of Oncology, Barcelona, Spain
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT06608940
- Locations
- 🇺🇸
Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer Tumors
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06584435
- Locations
- 🇨🇳
Changyi Quan, Tianjin, Tianjin, China
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 25
- Registration Number
- NCT06564623
- Locations
- 🇺🇸
SKCCC Johns Hopkins Medical Institution, Baltimore, Maryland, United States
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 32
- Registration Number
- NCT06526104
- Locations
- 🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 660
- Registration Number
- NCT06109272
- Locations
- 🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 265506, Rome, Roma, Italy
🇺🇸City of Hope /ID# 261468, Duarte, California, United States
🇺🇸City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California, United States
Radioembolization with Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT06058663
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 28
- Registration Number
- NCT06017297
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.